Cabometyx – Cabozantinib Tablets
Description
CABOZANTINIB (CABOMETYX) TABLETS – TREATMENT OF PATIENTS WITH CUTTING-EDGE RENAL CELL CARCINOMA
Cabometyx (cabozantinib) is approved for the treatment of patients with advanced renal cell carcinoma (a type of kidney cancer) who have previously been treated with angiogenic therapy1,2 (treatment that prevents the formation of new recruits vessels that supply the tumor with oxygen and nutrients5). In December 2017, the FDA expanded the approval to include previously untreated patients with advanced renal cell carcinoma (RCC).
USES:
Cabozantinib, the active ingredient in Cabometyx, is a tyrosine kinase inhibitor. This means that it impedes the movement of chemicals known as tyrosine kinases. These proteins are found in disease cells, where they initiate a number of processes such as cell division and the formation of new recruit vessels to supply cancer. Cabometyx (cabozantinib) reduces cancer development and spread by inhibiting the action of these proteins in malignant growth cells.
